Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
Clinical trial NCT06531291 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06531291
- Sponsor
- RenJi Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-10
- Primary completion
- 2027-08-09
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.